Hemispherian
The company focuses on developing a novel class of small-molecule drugs that target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.
Oslo, Norwayhemispherian.com ↗
Total raised
€14M
€14,112,028
Funding rounds
3
Investors
5
distinct backers
Active since
2022-05
latest 2022-11
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood28
base rate 44% for Series A
- ▼ Overdue vs cohort gap
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood14
base rate 12% (2+ rounds)
- ▲ 3 rounds raised
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-11-24 | Series A | €2.8M | Kistefos,Kvantia,Meneldor,Steven Powell | View deal → |
| 2022-10-19 | Other | €10M | European Innovation Council (EIC) | View deal → |
| 2022-05-03 | Seed | €1.3M | Meneldor | View deal → |
Related news
- Hemispherian Raises USD$2.9M in First Tranche of Series A Fundingfinsmes.com · 2022-11
- Hemispherian Raises EUR10M in Financingfinsmes.com · 2022-10
- Norwegian innovative preclinical pharmaceutical company raised $1.4M seedarcticstartup.com · 2022-05
Similar companies
same sector or country- Visma€3.0BNorway · Software
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Adevinta€1.9BNorway · Marketing
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech